Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 8/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | TIPARP | Q7Z3E1 | 4/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 5/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30390270 | 1.00 | PANK3 (0.56) | PANK3SIGMAR1TIPARPCHRM1PARP1 | |
| SCHEMBL21521827 | 0.96 | PANK3 (0.55) | PANK3SIGMAR1TIPARPCHRM1PARP1 | |
| SCHEMBL21521550 | 0.94 | PANK3 (0.58) | PANK3SIGMAR1TIPARPCHRM1PARP1 | |
| SCHEMBL31464881 | 0.94 | PANK3 (0.58) | PANK3SIGMAR1TIPARPCHRM1PARP1 | |
| SCHEMBL30859971 | 0.88 | PANK3 (0.60) | PANK3SIGMAR1TIPARPCHRM1PARP1 | |
| SCHEMBL31464972 | 0.88 | PANK3 (0.60) | PANK3SIGMAR1TIPARPCHRM1PARP1 | |
| SCHEMBL25269821 | 0.84 | SMN1; SMN2 (0.56) | PANK3SIGMAR1CHRM1 | |
| SCHEMBL31464937 | 0.80 | PANK3 (0.57) | PANK3TIPARPCHRM1PARP1PARP2 | |
| SCHEMBL30860008 | 0.80 | PANK3 (0.57) | PANK3TIPARPCHRM1PARP1PARP2 | |
| SCHEMBL26291082 | 0.80 | PANK3 (0.59) | PANK3TIPARPCHRM1PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4423078-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118139858-A | Pyrazin-3 (2H) -one derivatives | 吉利德科学公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2023076983-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076983-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | PANK3 845/4885SIGMAR1 1893/4885TIPARP 3487/4885 |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | PANK3 845/4885SIGMAR1 1893/4885TIPARP 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.